How many stocks are there of Pharnext?
The current number of stocks of Pharnext is 2,370 undefined.
Pharnext Stocks 2024
Pharnext Stocks
2,370
Ticker
ALPHA.PA
ISIN
FR0011191287
WKN
A2AM02
In 2024, Pharnext had 2,370 outstanding stocks, a 0% change from the 2,370 stocks in the previous year.
The Pharnext Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2026e | 0 |
| 2025e | 0 |
| 2024e | 0 |
| 2023e | 0 |
| 2022 | 0 |
| 2021 | 0 |
| 2020 | 0 |
| 2019 | 0 |
| 2018 | 0 |
| 2017 | 0 |
| 2016 | 0 |
| 2015 | 6.43 |
| 2014 | 4.02 |
| 2013 | 4.02 |
Pharnext shares outstanding FR0011191287 · A2AM02
The number of shares was Pharnext in 2023 — This indicates how many shares 2,370 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Pharnext earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Pharnext's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Pharnext’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharnext's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2013 | 4.02 M Aktien |
| 2014 | 4.02 M Aktien |
| 2015 | 6.43 M Aktien |
| 2016 | 1,690 Aktien |
| 2017 | 2,190 Aktien |
| 2018 | 2,370 Aktien |
| 2019 | 2,370 Aktien |
| 2020 | 2,370 Aktien |
| 2021 | 2,370 Aktien |
| 2022 | 2,370 Aktien |
| 2023e | 2,370 Aktien |
| 2024e | 2,370 Aktien |
| 2025e | 2,370 Aktien |
| 2026e | 2,370 Aktien |
Pharnext Aktienanalyse
What does Pharnext do?
Pharnext SA is a French biopharmaceutical company specializing in the development of innovative therapies for neurological diseases. The company was founded in 2007 by Professor Daniel Cohen and is headquartered in Paris. Pharnext's focus is on identifying synergistic effects of existing drugs to develop novel and effective therapies. The business model of Pharnext is based on the concept of "pleotherapy," which involves using multiple drugs simultaneously. These drug combinations are optimized to act synergistically and achieve better treatment outcomes than individual drugs alone. This allows Pharnext to achieve higher efficacy and lower toxicity. Pharnext operates in two main areas: developing therapies for neurological diseases such as Alzheimer's, Parkinson's, MND (Motoneuron Disease), Charcot-Marie-Tooth (CMT), and other rare diseases, and providing analysis and diagnostic tools for rare diseases. A significant product of Pharnext is PXT3003, a proprietary combination of three drugs for the treatment of Charcot-Marie-Tooth (CMT). PXT3003 is in Phase III clinical development and has the potential to be a groundbreaking therapy for one of the most common hereditary neuropathies worldwide. The company is also developing other products, such as PXT864 for Alzheimer's, PXT002331 for Parkinson's, and PXT002331 for MND, all of which are in clinical development. Pharnext also collaborates with other biotech and pharmaceutical companies to leverage synergies and advance the development of its therapies. For example, the company collaborates with Ipsen for the development of PXT3003 and with Galapagos for the development of drug candidates against inflammatory diseases. Overall, Pharnext aims to take a leading role in the development of therapies for neurological diseases. The company focuses on innovative approaches to maximize the potential of drug combinations and develop novel and effective therapies. Pharnext ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Pharnext's Shares Outstanding
Pharnext's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Pharnext’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Pharnext’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Pharnext’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Pharnext stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Pharnext are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Pharnext evolved in recent years?
The number of shares of Pharnext has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Pharnext as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Pharnext?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Pharnext pay?
Over the past 12 months, Pharnext paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharnext is expected to pay a dividend of 0 EUR.
What is the dividend yield of Pharnext?
The current dividend yield of Pharnext is .
When does Pharnext pay dividends?
Pharnext pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharnext?
Pharnext paid dividends every year for the past 0 years.
What is the dividend of Pharnext?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharnext located?
Pharnext is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharnext kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharnext from 9/11/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.
When did Pharnext pay the last dividend?
The last dividend was paid out on 9/11/2024.
What was the dividend of Pharnext in the year 2023?
In the year 2023, Pharnext distributed 0 EUR as dividends.
In which currency does Pharnext pay out the dividend?
The dividends of Pharnext are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharnext
Our stock analysis for Pharnext Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharnext Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
